Comparison of the AdvanSure human papillomavirus screening real-time PCR, the abbott RealTime high risk human papillomavirus test, and the hybrid capture human papillomavirus DNA test for the detection of human papillomavirus

Annals of Laboratory Medicine

Volumn 32, Issue 3, 2012, Pages 201-205

  Hwang, Yusun ^a   Lee, Miae ^a  

^a Ewha Womans University   (South Korea)

Author keywords

HPV type 16; Human papillomavirus; Real time PCR

Indexed keywords

EID: 84861404256     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2012.32.3.201     Document Type: Article

References (16)

1. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(S3):171-7.
2. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
3. Poljak M and Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139-62.
4. Mo LZ, Monnier-Benoit S, Kantelip B, Petitjean A, Riethmuller D, Prétet JL, et al. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. J Clin Virol 2008;41:104-10. (Pubitemid 351187890)
5. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101. (Pubitemid 44116919)
6. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007;104:232-46. (Pubitemid 46054137)
7. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 2009;125:2489-96.
8. Seme K, Fujs K, Kocjan BJ, Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods 2006;134:252-6.
9. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008;46:2595-604.
10. Schutzbank TE, Jarvis C, Kahmann N, Lopez K, Weimer M, Yount A. Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J Clin Microbiol 2007;45:4067-9. (Pubitemid 350274898)
11. Eder PS, Lou J, Huff J, Macioszek J. The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform. J Clin Virol 2009;45(S1):S85-92.
12. Instructor's insert of AdvanSure HPV Screening real-time PCR (LG Life Science, Korea, 2010)
13. Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, et al. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J Clin Virol 2010;48:246-50.
14. Huang S, Tang N, Mak WB, Erickson B, Salituro J, Li Y, et al. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol 2009;45(S1):S13-7.
15. Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol Alp Panonica Adriat 2009;18:94-103.
16. Instructor's insert of Abbott RealTime High Risk HPV (Abbott molecular, USA, 2010)